HLS 13RS-142 ORIGINAL
Page 1 of 5
CODING: Words in struck through type are deletions from existing law; words underscored
are additions.
Regular Session, 2013
HOUSE BILL NO. 15
BY REPRESENTATIVE MACK
Prefiled pursuant to Article III, Section 2(A)(4)(b)(i) of the Constitution of Louisiana.
CONTROLLED SUBSTANCES: Adds certain compounds to the Schedule I classification
of controlled dangerous substances
AN ACT1
To amend and reenact R.S. 40:964(Schedule I)(E)(9)(i) and (iii) and (F) and to enact R.S.2
40:961(26.1), relative to controlled dangerous substances; to provide with respect to3
certain chemical groups within the cathinone Schedule I stimulants; to add4
substances to the listing of synthetic cannabinoids in Schedule I; to provide for5
definitions; to provide for certain exceptions; and to provide for related matters.6
Be it enacted by the Legislature of Louisiana:7
Section 1. R.S. 40:964(Schedule I)(E)(9)(i) and (iii) and (F) are hereby amended and8
reenacted and R.S. 40:961(26.1) is hereby enacted to read as follows: 9
§961. Definitions10
As used in this Part, the following terms shall have the meaning ascribed to11
them in this Section unless the context clearly indicates otherwise:12
* * *13
(26.1) "Nitrogen-heterocyclic analog" means a nitrogen-heterocyclic analog14
of a synthetic cannabinoid which has a single carbon atom in a cyclic structure of a15
compound replaced by a nitrogen atom.16
* * *17 HLS 13RS-142 ORIGINAL
HB NO. 15
Page 2 of 5
CODING: Words in struck through type are deletions from existing law; words underscored
are additions.
§964. Composition of schedules1
Schedules I, II, III, IV, and V shall, unless and until added to pursuant to R.S.2
40:962, consist of the following drugs or other substances, by whatever official3
name, common or usual name, chemical name, or brand name designated:4
SCHEDULE I5
* * *6
E. Stimulants. Unless specifically excepted, or contained within a7
pharmaceutical product approved by the United States Federal Food and Drug8
Administration, or unless listed in another schedule, any material, compound,9
mixture, or preparation which contains any quantity of the following substances10
having a stimulant effect on the central nervous system including its salts, isomers,11
esters, or ethers and salts of isomers, esters, or ethers whenever the existence of such12
salts, isomers, esters, or ethers and salts of isomers, esters, or ethers is possible13
within the specific chemical designation:14
* * *15
(9) 2-amino-1-phenyl-1-propanone (cathinone) or variation in any of the16
following ways:17
(i) By substitution in the phenyl ring to any extent with alkyl, hydroxyl18
alkoxy, alkylenedioxy, haloalkyl or halide substituents, whether or not further19
substituted in the phenyl ring by one or more other univalent substituents.20
(ii) By substitution at the 3-position with an alkyl substituent.21
(iii) By substitution at the 2-amino nitrogen atom with alkyl, dialkyl, or22
benzyl groups, or methoxybenzyl groups, or by inclusion of the 2-amino nitrogen23
atom in a cyclic structure.24
F. Synthetic cannabinoids. Unless specifically excepted, or contained within25
a pharmaceutical product approved by the United States Food and Drug26
Administration, or unless listed in another schedule, any material, compound,27
mixture, or preparation, which contains any quantity of a synthetic cannabinoid28
found to be in any of the following chemical groups, or any of those groups which29 HLS 13RS-142 ORIGINAL
HB NO. 15
Page 3 of 5
CODING: Words in struck through type are deletions from existing law; words underscored
are additions.
contain any synthetic cannabinoid salts, isomers, or salts of isomers, or nitrogen-1
heterocyclic analogs, whenever the existence of such salts, isomers, or salts of2
isomers, or nitrogen-heterocyclic analogs is possible within the specific chemical3
designation, including all synthetic cannabinoid chemical analogues in such groups:4
(1) Naphthoylindoles : any compound containing a 3-(1-naphthoyl)indole5
structure, whether or not substituted in the indole ring to any extent or the naphthyl6
ring to any extent.7
(2) Naphthylmethylindoles : any compound containing a 1-H-indol-3-yl-(1-8
naphthyl)methane structure, whether or not substituted in the indole ring to any9
extent or the naphthyl ring to any extent.10
(3) Naphthoylpyrroles : any compound containing a 3-(1-naphthoyl)pyrrole11
structure, whether or not substituted in the pyrrole ring to any extent or the naphthyl12
ring to any extent.13
(4) Naphthylmethylindenes : any compound containing a 1-(1-14
naphthylmethyl)indene structure, whether or not substituted in the indene ring to any15
extent or the naphthyl ring to any extent.16
(5) Phenylacetylindoles : any compound containing a 3-phenylacetylindole17
structure, whether or not substituted in the indole ring to any extent or the phenyl18
ring to any extent.19
(6) Cyclohexylphenols : any compound containing a 2-(3-20
hydroxycyclohexyl)phenol structure, whether or not substituted in the cyclohexyl21
ring to any extent or the phenyl ring to any extent.22
(7) Dibenzopyrans whether or not substituted in the cyclohexyl ring to any23
extent or the phenyl ring to any extent.24
(8)(7) Benzoylindoles : any compound containing a 3-(benzoyl)indole25
structure, whether or not substituted in the indole ring to any extent or the phenyl26
ring to any extent.27 HLS 13RS-142 ORIGINAL
HB NO. 15
Page 4 of 5
CODING: Words in struck through type are deletions from existing law; words underscored
are additions.
(9)(8) (1-pentylindol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone1
Tetrahydrodibenzopyr ans whether or not substituted in the tricyclic ring system2
except where contained in cannabis or cannabis resin.3
(10)(9) (1-(5-fluoropenty l)indol-3-y l)4
-(2,2,3,3-tetramethylcyclopropy l)methanone Hexahydrodibenzopyrans whether or5
not substituted in the tricyclic ring system except where contained in cannabis or6
cannabis resin.7
(10) Cyclopropanoylindoles: any compound containing a 3-8
(cyclopropanoyl)indole structure, whether or not substituted in the indole ring to any9
extent or the cyclopropyl ring to any extent.10
(11) Adamantoylindoles: any compound containing a 3-(1-11
adamantoyl)indole structure, whether or not further substituted in the indole ring to12
any extent or whether or not substituted in the adamantyl ring to any extent.13
(12) Naphthylamidoindoles: any compound containing a14
N-(naphthyl)-indole-3-carboxamide structure, whether or not further substituted in15
the indole ring to any extent or whether or not substituted in the naphthyl ring to any16
extent.17
(13) Quinolinylindolecarboxylates: any compound containing a18
quinolin-8-yl-1H-indole-3-carboxylate structure, whether or not substituted in the19
indole ring to any extent or the quinloline ring to any extent.20
* * *21
DIGEST
The digest printed below was prepared by House Legislative Services. It constitutes no part
of the legislative instrument. The keyword, one-liner, abstract, and digest do not constitute
part of the law or proof or indicia of legislative intent. [R.S. 1:13(B) and 24:177(E)]
Mack HB No. 15
Abstract: Adds certain compounds to the Schedule I classification of controlled dangerous
substances.
Present law provides for the classification of controlled dangerous substances in Schedules
I through V. HLS 13RS-142 ORIGINAL
HB NO. 15
Page 5 of 5
CODING: Words in struck through type are deletions from existing law; words underscored
are additions.
Proposed law adds certain chemical groups to the Schedule I listing of stimulants known as
cathinones and adds additional substances to the Schedule I listing of synthetic cannabinoids.
Proposed law provides a definition of "nitrogen-heterocyclic analog".
(Amends R.S. 40:964(Schedule I)(E)(9)(i) and (iii) and (F); Adds R.S. 40:961(26.1))